Cardiac allograft vasculopathy remains a major limiting factor in the long-term survival of the heart transplant recipient. Our understanding of its pathogenesis is continuously evolving as advances in imaging modalities have allowed a direct window into the natural history of the disease. Innovation in diagnostic modalities has spurred the proliferation of prognostic tools and biomarkers. And in parallel, pharmacological advances have emerged that have helped ameliorate the disease’s progressive course.
1 Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
Received 29 October 2018. Revision received 6 February 2019.
Accepted 28 February 2019.
The authors declare no conflicts of interest.
Correspondence: Jon A. Kobashigawa, MD, 127 S. San Vicente Blvd, Third Floor Cardiology A3107, Los Angeles, CA 90048. (Kobashigawaj@cshs.org).